Literature DB >> 9626160

Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.

N Mitsiades1, V Poulaki, V Kotoula, G Mastorakos, S Tseleni-Balafouta, D A Koutras, M Tsokos.   

Abstract

Hashimoto's thyroiditis (HT) is an autoimmune disorder characterized by diffuse thyroid lymphocytic infiltration and follicle destruction. Cross-linking of the Fas receptor with its own ligand (FasL) triggers apoptosis in various systems, whereas the Bcl-2 protooncogene inhibits apoptotic cell death. The involvement of Fas, FasL, and Bcl-2 in the apoptotic process in HT was evaluated in 15 thyroid tissue samples from patients with HT stained for apoptosis and for Fas, FasL, and Bcl-2 protein expression. Eight samples from healthy thyroid tissue were used for comparison. Thyroid follicles in HT samples exhibited strong staining for Fas and FasL and a high percentage of apoptosis (30.3 +/- 14.5%, mean +/- SD), in contrast to normal control follicles that exhibited moderate Fas, minimal or no FasL, and hardly any apoptosis. Immunostaining for Bcl-2 was high in normal, and weak in involved, thyroid follicles. Infiltrating lymphocytes stained weakly for FasL and strongly for Bcl-2. We conclude that follicular cells in HT undergo apoptosis by concomitant up-regulation of FasL and Fas and down-regulation of Bcl-2 protein. The lymphocytes do not seem to be directly engaged in the process with their own FasL, but they may provide the appropriate cytokine milieu that, in turn, up-regulates Fas and/or FasL leading to apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626160     DOI: 10.1210/jcem.83.6.4853

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro.

Authors:  F Podestà; G Romeo; W H Liu; S Krajewski; J C Reed; C Gerhardinger; M Lorenzi
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Fas and Fas ligand expression in cystic fibrosis airway epithelium.

Authors:  I Durieu; C Amsellem; C Paulin; M T Chambe; J Bienvenu; G Bellon; Y Pacheco
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

3.  Fas/FasL mediated apoptosis of thyrocytes in Graves' disease.

Authors:  N Sera; A Kawakami; T Nakashima; H Nakamura; M Imaizumi; T Koji; Y Abe; T Usa; T Tominaga; E Ejima; K Ashizawa; N Yokoyama; N Ishikawa; K Ito; K Eguchi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 4.  The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives.

Authors:  Efstratios Kardalas; Evangelos Sakkas; Marek Ruchala; Djuro Macut; George Mastorakos
Journal:  Rev Endocr Metab Disord       Date:  2021-09-16       Impact factor: 6.514

5.  Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

Authors:  N Mitsiades; V Poulaki; V Kotoula; A Leone; M Tsokos
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

6.  Hashimoto's Thyroiditis: From Genes to the Disease.

Authors:  Katja Zaletel; Simona Gaberšček
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

Review 7.  Fas-FasL in Hashimoto's thyroiditis.

Authors:  G Stassi; A Zeuner; D Di Liberto; M Todaro; L Ricci-Vitiani; R De Maria
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

8.  Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases.

Authors:  G Bona; S Defranco; A Chiocchetti; M Indelicato; A Biava; D Difranco; I Dianzani; U Ramenghi; A Corrias; G Weber; V De Sanctis; L Iughetti; G Radetti; U Dianzani
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.